BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Hakko, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

DBV expects delay for peanut allergy product  DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date for its peanut allergy therapy may be extended as FDA has raised questions on the long-term efficacy...
BioCentury | Jan 24, 2020
Product Development

The new drug development -- collaborative and people-powered

In recent years, the healthcare ecosystem has been experiencing a paradigm shift in how it engages with the people at its center: patients. Patients are demanding to be viewed first as people, with lives and...
BC Extra | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

Trio of approvals from China’s NMPA   China’s National Medical Products Administration approved NDAs for Lokelma sodium zirconium cyclosilicate from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat hyperkalemia and anti-PCSK9 mAb Praluent alirocumab from Sanofi (Euronext:SAN;...
BC Extra | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BC Extra | Sep 26, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BC Extra | Aug 12, 2019
Company News

Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more

Jack Bailey will step down as president of U.S. Pharmaceuticals at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at year end. He will be replaced by Maya Martinez-Davis, who is regional president for Latin America at the EMD...
BC Extra | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
BC Week In Review | Feb 22, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Feb. 20, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic...
Items per page:
1 - 10 of 1499
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Hakko, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

DBV expects delay for peanut allergy product  DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date for its peanut allergy therapy may be extended as FDA has raised questions on the long-term efficacy...
BioCentury | Jan 24, 2020
Product Development

The new drug development -- collaborative and people-powered

In recent years, the healthcare ecosystem has been experiencing a paradigm shift in how it engages with the people at its center: patients. Patients are demanding to be viewed first as people, with lives and...
BC Extra | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

Trio of approvals from China’s NMPA   China’s National Medical Products Administration approved NDAs for Lokelma sodium zirconium cyclosilicate from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat hyperkalemia and anti-PCSK9 mAb Praluent alirocumab from Sanofi (Euronext:SAN;...
BC Extra | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BC Extra | Sep 26, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BC Extra | Aug 12, 2019
Company News

Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more

Jack Bailey will step down as president of U.S. Pharmaceuticals at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at year end. He will be replaced by Maya Martinez-Davis, who is regional president for Latin America at the EMD...
BC Extra | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
BC Week In Review | Feb 22, 2019
Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Feb. 20, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic...
Items per page:
1 - 10 of 1499